Abstract
BackgroundTreatment-induced bone loss is a risk factor for skeletal morbidity in cancer patients. Despite the widespread use of immune checkpoint inhibitors (ICIs) their impact on bone health is still poorly...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
